Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.

U.S. stock futures (ES00) (NQ00) weakened after the S&P 500 SPX finished at its lowest level since mid-January. Bitcoin (BTCUSD) traded below $90,000, and the yield on the 10-year Treasury declined.